ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00721045
Recruitment Status : Completed
First Posted : July 23, 2008
Last Update Posted : May 20, 2015
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2011
  Actual Study Completion Date : July 2013